Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GNR-055 in Healthy Volunteers
NCT04539340Phase 1Completed
- Sponsor
- Generium
- Start
- Feb 2020
- Primary completion
- Sep 2020
- Modality
- Antibody Conjugates, Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of verenafusp alfa in mucopolysaccharidosis type II (5 cohorts), sponsored by Generium. Primary endpoint: Number of participants with Adverse Events at Day 7. Started Feb 2020; status: completed.
02
Drugs
verenafusp alfa
03
Conditions
mucopolysaccharidosis type II
Beyond the preview
Go deeper on NCT04539340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04539340.